Design Therapeutics (DSGN) Earnings Date & Reports

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

DSGN is expected to report earnings to fall 4.29% to -29 cents per share on August 11

Design Therapeutics DSGN Stock Earnings Reports

Q2'25

Est.

$-0.30

Q1'25

Missed

by $0.02

Q4'24

Beat

by $0.02

Q3'24

Beat

by $0.01

Q2'24

Beat

by $0.02

The last earnings report on May 07 showed earnings per share of -31 cents, missing the estimate of -28 cents. With 217.90K shares outstanding, the current market capitalization sits at 198.69M.

View a ticker or compare two or three

Compare

DSGN